ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1830

The Role of Tripartite Motif-Containing 21 in Interferon Signature of Systemic Lupus Erythematosus

Reikou Kamiyama1, Ryusuke Yoshimi1, Yumiko Sugiyama1, Yosuke Kunishita1, Daiga Kishimoto1, Toshinori Tsukahara1, Yukiko Asami1, Yohei Kirino1, Mitsuhiro Takeno2, Atsuhisa Ueda1, Keiko Ozato3 and Hideaki Nakajima1, 1Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 3Program in Genomics of Differentiation, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Interferons and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Although the increased expression of type I interferon (IFN)-inducible genes, called “IFN signature”, has been suggested to have important roles in the pathogenesis of systemic lupus erythematosus (SLE), its mechanism still remains unclear. Recent studies in vitro or with mice suggest that tripartite motif-containing 21 (TRIM21), an autoantigen also called Ro52 or SSA1, is involved in the regulation of type I IFN production as an E3 ubiquitin ligase for IFN regulatory factors (IRF). Here, we investigated the pathological role of TRIM21 in SLE.

Methods: We collected peripheral blood mononuclear cells (PBMC) from 20 patients who met the 1997 ACR SLE classification criteria and 24 healthy controls (HC), and analyzed the mRNA expression of TRIM21, type I IFNs, type I IFN-inducible genes by qPCR. We also quantified protein levels of TRIM21 and IRF proteins in the PBMC from SLE patients and HC by Western blot analysis. To evaluate the degree of ubiquitylation of IRF proteins, PBMC were incubated with a proteasome inhibitor MG-132.

Results: There were no significant differences in age and sex ratio between patients with SLE and HC (41.2 ± 13.9 vs 34.1 ± 10.4 years, p = 0.09, and 67% vs 75% (female), p = 0.73, respectively). Seven patients (35%) with SLE had anti-TRIM21 autoantibody while all of HC were negative for anti-TRIM21 antibody. The mRNA and protein levels of TRIM21 were significantly higher in PBMC from patients with SLE as compared to HC. Although transcript levels of multiple genes including MX1, IFI27, IFI44 and SIGLEC1, known as type IFN-inducible genes, were significantly higher in patients with SLE as compared to HC, there was no significant difference in mRNA levels of type I IFNs themselves between SLE and HC. In HC, IFN-α and IFN-β mRNA levels were negatively correlated with the level of TRIM21 transcript (r = -0.52, p = 0.0087, and r = -0.48, p = 0.018, respectively). On the other hand, there was no significant correlation between TRIM21 transcript level and IFN-α mRNA (r = 0.21, p = 0.37) or IFN-β mRNA level (r = 0.24, p = 0.30) in SLE. To investigate the degrees of ubiquitylation of IRF proteins, PBMC from patients with SLE and HC were incubated with MG-132. Although the protein expression levels of IRF3 and IRF5 were significantly increased by MG-132 in PBMC from HC, the effect of MG-132 was not observed in PBMC from SLE patients.

Conclusion: This study suggests that dysregulation of E3 ubiquitin ligase activity of TRIM21 for IRF proteins may be associated with the increased expression of type I IFN-inducible genes in SLE.


Disclosure: R. Kamiyama, None; R. Yoshimi, None; Y. Sugiyama, None; Y. Kunishita, None; D. Kishimoto, None; T. Tsukahara, None; Y. Asami, None; Y. Kirino, None; M. Takeno, None; A. Ueda, None; K. Ozato, None; H. Nakajima, None.

To cite this abstract in AMA style:

Kamiyama R, Yoshimi R, Sugiyama Y, Kunishita Y, Kishimoto D, Tsukahara T, Asami Y, Kirino Y, Takeno M, Ueda A, Ozato K, Nakajima H. The Role of Tripartite Motif-Containing 21 in Interferon Signature of Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-role-of-tripartite-motif-containing-21-in-interferon-signature-of-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-role-of-tripartite-motif-containing-21-in-interferon-signature-of-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology